A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eisai Pharmaceuticals India Pvt. Ltd
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants prescribed perampanel for the adjunctive treatment of partial onset seizures based on independent clinical judgment of treating physicians.
You may not be if
Participation in another study involving administration of an investigational drug or device whilst participating in this observational study.
Hypersensitivity \[allergic\] to perampanel.
Clareo Health | A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older
